- Receipt of critical license marks significant milestone for first commercial-scale manufacturing facility for Alpha DaRT ®, the innovative alpha-radiation cancer therapy designed for potent and ...
JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has ...
CLEVELAND, Ohio — The Ohio State University’s James Cancer Hospital has treated the world’s first brain cancer patient to receive a new radiation technology that attacks tumors from within, the ...
Hosted on MSN
Alpha Tau expands Alpha DaRT into recurrent prostate cancer: What investors should watch
Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study. Study Overview – Alpha Tau Medical Ltd. (NASDAQ: DRTS) is launching a new safety study titled “A Safety Study of ...
- Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and ...
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The ...
HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor treatment device 'Alpha DaRT (Diffusing Alpha Radiation Therapy),' developed by Alpha Tau Medical Ltd.
This animation illustrates how targeted alpha therapy delivers powerful radiation directly to cancer cells while sparing healthy tissue. Credit: ORNL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results